Patents by Inventor Bertrand Leblond

Bertrand Leblond has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9902710
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: February 27, 2018
    Assignees: EXONHIT THERAPEUTICS, SA, ALLERGAN, INC.
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 9828349
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: November 28, 2017
    Assignees: EXONHIT THERAPEUTICS SA, ALLERGAN, INC.
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9670181
    Abstract: The invention relates to compounds of the formula wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: June 6, 2017
    Assignees: ALLERGAN, INC., EXONHIT THERAPEUTICS SA
    Inventors: Bertrand Leblond, Cedric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • DYRK1 inhibitors and uses thereof
    Patent number: 9446044
    Abstract: The present invention relates to novel thiazolo[5,4-f]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: September 20, 2016
    Assignee: DIAXONHIT
    Inventors: Bertrand Leblond, Anne-Sophie Casagrande, Laurent Desire, Alicia Foucourt, Thierry Besson
  • SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20160264549
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: October 16, 2015
    Publication date: September 15, 2016
    Applicant: EXONHIT THERAPEUTICS, SA
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 9399628
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: July 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY
    Publication number: 20160083371
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Application
    Filed: November 30, 2015
    Publication date: March 24, 2016
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
    Patent number: 9278943
    Abstract: The compounds shown by the structural formulas below have analgesic effect and are used in compositions and methods for treating mammal in need of such treatment.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: March 8, 2016
    Assignees: Exonhit Therapeutics SA, Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello, Fabien (Jacques) Schweighoffer
  • Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9200016
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: December 1, 2015
    Assignees: Allergan, Inc., Exonhit Therapeutics, SA
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20150158895
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 11, 2015
    Applicant: Allergan, Inc.
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 8927589
    Abstract: Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 6, 2015
    Assignee: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
  • SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20140309253
    Abstract: The invention relates to compounds of the formula wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Inventors: Bertrand Leblond, Cedric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • DYRK1 INHIBITORS AND USES THEREOF
    Publication number: 20140275064
    Abstract: The present invention relates to novel thiazolo[5,4-f]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.
    Type: Application
    Filed: August 17, 2012
    Publication date: September 18, 2014
    Applicant: DIAXONHIT
    Inventors: Bertrand Leblond, Anne-Sophie Casagrande, Laurent Desire, Alicia Foucourt, Thierry Besson
  • Compounds having analgesic and/or immunostimulant activity
    Patent number: 8835463
    Abstract: The compounds shown by their structural formulas in the specification have analgesic and or immunostimulant activity in mammals.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 16, 2014
    Assignees: Allergan, Inc., Exonhit Therapeutics SA
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
  • Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
    Patent number: 8772316
    Abstract: The invention relates to compounds of the formula wherein R?, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: July 8, 2014
    Assignees: Allergan, Inc., Exonhit Therapeutics SA
    Inventors: Bertrand Leblond, John E. Donello, Cédric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Désiré, Matthew P. Pando, Rong Yang
  • 1-ARYL -1-HYDROXY -2,3-DIAMINO-PROPYL AMIN ES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY
    Publication number: 20130310383
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Application
    Filed: July 24, 2013
    Publication date: November 21, 2013
    Applicant: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 8513288
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: August 20, 2013
    Assignees: Allergan, Inc., ExonHit Therapeutics SA
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS
    Publication number: 20130131018
    Abstract: The present invention relates generally to substituted isoquinolines and their use as tubulin polymerization inhibitors. In particular, the invention relates to substituted isoquinolines which possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 23, 2013
    Applicant: Exonhit S.A.
    Inventors: Bertrand Leblond, Thierry Taverne, Eric Beausoleil, Cédric Chauvignac, Anne-Sophie Casagrande, Laurent Desire
  • 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 8431599
    Abstract: Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 30, 2013
    Assignees: Allergan, Inc., ExonHit Therapeutics SA
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
  • 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY
    Publication number: 20130005717
    Abstract: Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 3, 2013
    Applicants: ExonHit Therapeutics SA, Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello